As cRCC is a highly vascular tumor, over the past years, the treatment of RCC has been focused on the inhibition of VEGFA/KDR signaling pathway with an increasing number of new drugs, including tyrosine kinase inhibitors as well as anti-VEGFA humanized monoclonal antibody [7]. This evidence concerns the gene VEGFA and renal cell carcinoma.